Jade

Method of action: Contraceptive, Contraceptive With Antimineralcorticoid And Antiandrogenic Components, Estrogen-Progestational, Monophasic Contraceptive Combination, Sex Hormones And Modulators Of The Genital System

Treatment option: Birth Control, Zits

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jade

What is Jade? (Product Overview and Key Characteristics)

Property	Description
Active ingredient	Drospirenone and Ethinyl Estradiol
Form	Oral Tablet
Pharmacological class	Combined Hormonal Contraceptive (CHC)
Common use	Pregnancy Prevention (Contraception)
Origin	Synthetic

What Type of Medicine is Jade and How is it Classified?

Jade is a synthetic, prescription-only drug defined as a Combination Oral Contraceptive (COC). It is pharmacologically classified as a Combined Hormonal Contraceptive (CHC), falling under the category of Sex hormones and modulators of the genital system. This classification confirms that the medication achieves its effect through systemic hormonal action. The formulation is a tablet designed for oral administration and is typically monophasic, delivering consistent levels of hormones across the active days. The combination is recognized for providing reliable, reversible contraception.

What Hormones is Jade Composed of?

The two active ingredients in Jade are Drospirenone (a synthetic progestin) and Ethinyl Estradiol (a synthetic estrogen). The inclusion of both hormone types is a defining characteristic of this combination product. The progestin component, Drospirenone, is structurally related to spironolactone, which grants it antimineralocorticoid activity. This specific feature, which differentiates it from older progestins, provides a unique characteristic within the COC class. The availability of this specific Drospirenone/Ethinyl Estradiol combination under various generic and trade names is common across global markets.

What is the General Purpose of Jade?

The primary purpose of Jade is to provide effective pregnancy prevention (contraception). It is typically used by women of reproductive age who are sexually active and require a highly reliable form of hormonal birth control. The active ingredients work systemically, with the main mechanism being the inhibition of ovulation, preventing the ovaries from releasing an egg. The drug's dual hormonal action ensures reliable contraceptive efficacy by suppressing the hormonal cycle and also creating an environment (through altered cervical mucus and modified endometrial lining) unfavorable for conception.

What side effects are possible with Jade?

Official Regulatory Safety Profile

The information below is a summary of possible side effects and safety restrictions as documented in authoritative government regulatory sources (e.g., FDA, EMA) for the medicine Jade (abrocitinib).

This medicine is classified by regulatory agencies based on the frequency and severity of reported adverse reactions observed in clinical settings.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by how often they occurred in controlled studies:

Very Common (Affecting 1 in 10 or more people): Generally includes headache and nasopharyngitis.
Common (Affecting up to 1 in 10 people): Common reactions include nausea, dizziness, and Herpes Zoster (shingles).

System-Organ-Class (SOC) Safety Groups

Regulatory documents organize known side effects by the major body system affected:

Infections and Infestations: Includes infections such as nasopharyngitis and Herpes Zoster.
Gastrointestinal Disorders: Commonly includes nausea.
Blood and Lymphatic System Disorders: May involve hematological changes requiring laboratory monitoring.

Serious and Clinically Significant Adverse Reactions

Official safety documents highlight risks that are considered serious and require specific attention, including:

Serious Infections: Severe infections that may require hospitalization.
Malignancy: Documented reports of certain cancers, including Non-Melanoma Skin Cancer (NMSC).
Major Adverse Cardiovascular Events (MACE): Serious heart-related events.
Venous Thromboembolism (VTE): Blood clots in veins, such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Population-Specific Safety Considerations

Safety restrictions are documented for certain high-risk patient groups:

Patients Aged 65 Years and Older: Regulatory information indicates a higher incidence of serious adverse events, MACE, and malignancy in this population.
Patients with Pre-existing Cardiovascular Risks: Increased monitoring is required due to the risk of MACE and VTE.
Smokers (Current or Former): Specific restrictions or precautions may apply due to the increased risk of NMSC and VTE.

Safety Restrictions

Use is generally restricted in patients with known severe hypersensitivity to the medicine. The decision to treat patients with certain pre-existing conditions (e.g., high cardiovascular risk, history of certain cancers) must be based on a formal assessment of the benefit-risk balance as defined by regulatory standards.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for an overdose of Jade (Drospirenone and Ethinyl Estradiol), as stated in government regulatory documents.

Documented Overdose Manifestations

Feature	Official Regulatory Statement
Documented Manifestations	Nausea, Vomiting, and Withdrawal Bleeding (vaginal bleeding) in females.
Severity Classification	Acute ingestion is generally reported as not causing serious harmful effects.
Population Note	Withdrawal bleeding is a specific overdose manifestation noted in the female and adolescent female population.

Required Emergency Actions

The official prescribing information mandates specific actions following the suspected ingestion of an excessive dose:

Seek immediate medical attention for acute excessive ingestion.
Contact a Poison Control Center for guidance and professional medical direction.

Management is defined by regulatory authorities as symptomatic and supportive treatment. Official documentation states that no specific antidote is known for overdose with this medication. While acute overdose is generally classified as not serious, immediate medical evaluation remains the required course of action.

Therapeutic Uses of Jade

Quick Facts

Condition Addressed: Chronic iron overload from blood transfusions
Condition Addressed: Chronic iron overload in specific thalassemia syndromes

Jade is a medication used in the management of chronic iron overload in adults and children. This condition, which involves an accumulation of excess iron in the body, can occur due to various blood disorders.

The medication is specifically indicated to address chronic iron overload stemming from two primary contexts:

Repeat Blood Transfusions: It is used in patients who have developed iron accumulation due to frequent blood transfusions.
Non-Transfusion-Dependent Thalassemia: It may also contribute to the management of chronic iron overload in certain individuals with non-transfusion-dependent thalassemia syndromes, subject to specific criteria for liver iron concentration.

Treatment with this medication helps to control excess iron levels in the body.

Eligibility and Restrictions for Use

Official Eligibility Rules for Jade (Deferasirox)

The official population eligibility for Jade is strictly defined by age, organ function, and co-existing clinical conditions, as established in regulatory prescribing information.

Populations Allowed and Not Allowed

Eligibility Status	Patient Criteria (as defined in labeling)
Eligible Age Groups	Adults and children 2 years of age and older (for transfusional iron overload) or 10 years of age and older (for non-transfusion-dependent thalassemia).
Conditional Use	Patients with moderate hepatic impairment (Child-Pugh Class B) or baseline CrCl 40 to 60 mL/min are restricted populations.
Not Recommended	Use is not recommended in patients who are pregnant or breastfeeding, or those with severe hepatic impairment (Child-Pugh Class C).
Absolute Contraindication	Patients with severe renal impairment (eGFR < 40 mL/min/1.73m^2) or known hypersensitivity to the drug.

Comorbidity-Based Non-Eligibility

Jade must not be used in patients with specific severe conditions, including advanced malignancies, high-risk myelodysplastic syndromes (MDS), poor performance status, or platelet counts < 50 imes 10^9/ L. Use in children below the minimum age thresholds is documented as not established due to insufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Jade (Deferasirox) is defined by significant pharmacokinetic and pharmacodynamic interactions documented in regulatory information.

Official Interaction Statements

Classification	Interacting Agents (Examples)	Interaction Outcome
Contraindicated	Aluminum-containing antacids	Prohibited due to interference with absorption
Metabolic Induction	Theophylline (CYP1A2 Substrate)	Decreased systemic exposure of co-administered drug
Metabolic Inhibition	Repaglinide (CYP2C8 Substrate)	Increased systemic exposure of co-administered drug
Exposure Reduction	UGT Inducers (e.g., Rifampicin)	Decreased systemic exposure of Jade
Pharmacodynamic Risk	NSAIDs, Corticosteroids, Anticoagulants	Increased risk of serious gastrointestinal bleeding

Co-administration with aluminum-containing antacids is a formally contraindicated combination

. Regulatory documents state that Jade is a CYP1A2 inducer (reducing exposure of co-administered substrates) and a CYP2C8 inhibitor (increasing substrate exposure). The product label requires avoidance of bile acid sequestrants like Cholestyramine due to a reduction in Jade's systemic exposure. Furthermore, the risk of serious gastrointestinal hemorrhage is officially documented as being higher in the elderly patient population when co-administered with other agents that carry ulcerogenic potential. These restrictions define the formal constraints for combining Jade with other products.

Mechanism of Action

Blocking B-Cell Survival Signals

Jade's mechanism initiates with it acting as a receptor antagonist, binding specifically to the BAFF-R (B-cell activating factor receptor) located on the B-lymphocyte surface. This targeted molecular interaction blocks the binding of the natural ligand, BAFF, thereby disrupting the critical pro-survival signaling cascade within the B cell. This action results in the inhibition of B-cell activation and proliferation.

Targeted B-Cell Clearance

The structure of Jade also engages Fc gamma receptors on immune effector cells, such as Natural Killer (NK) cells. This recruitment triggers the active destruction process known as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), which facilitates the clearance of B cells from the bloodstream.

Modulation of Immune Homeostasis

The combined effect of blocking the survival pathway and targeted clearance leads to a reduction in the overall circulating B-lymphocyte count. This physiological change is characterized by altered activity within the adaptive immune system and a decreased contribution of the B-cell component to systemic processes.

Dosage and Administration Information

How to Use Jade: Administration Guidelines

Treatment with Jade (Deferasirox tablets for oral suspension) is administered via the oral route as a once-daily regimen. The usage protocol is defined by precise, body-weight-based dosing, specific preparation requirements, and strict timing relative to food intake.

Administration Scope

Feature	Detail
Route of administration	Oral.
Dosing schedule	Initial dose is 20 mg/kg daily for transfusional iron overload, or 10 mg/kg daily for non-transfusion-dependent thalassemia. Maximum daily dose is 40 mg/kg or 20 mg/kg, respectively.
Timing in relation to meals	Must be taken once daily on an empty stomach, at least 30 minutes before food.
Preparation requirements	Tablets must be fully dispersed in water, orange juice, or apple juice; they must not be chewed or swallowed whole.
Special procedural conditions	Dose adjustments of 5 or 10 mg/kg are typically made every 3 to 6 months based on iron levels. A 50% dose reduction is required for patients with moderate hepatic impairment.

Resulting Procedural Structure

The usage protocol requires a specific sequence for administration:

Disperse the calculated, whole number of tablets completely in one of the approved liquids (water, orange juice, or apple juice).
Consume the entire suspension at the same time each day.
Do not consume food until at least 30 minutes after taking the dose.

This regimen is structured around strict timing and preparation steps to ensure consistent delivery of the medicine, with continuation of therapy being contingent on the periodic monitoring of iron indicators.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Jade

Evidence for Use in Pregnancy Prevention (Contraception)

Research explored the medication in studies examining the rate of pregnancy. These studies primarily consist of non-comparative efficacy studies and large-scale post-marketing data collections. The main measure collected is the annual rate of pregnancy (Pearl Index), which describes group patterns observed in the studies. Researchers also monitored outcomes by assessing measures of menstrual cycle regularity and bleeding/spotting patterns. The collected data show patterns related to measures of menstrual cycle regularity.

Evidence for Use in Moderate Acne Vulgaris

The evidence for this indication was primarily derived from randomized, double-blind trials where the medication was compared against an inactive control (placebo). These studies were conducted in women who had moderate acne and were also suitable candidates for using an oral contraceptive. Researchers examined outcomes by measuring changes in the counts of inflammatory and non-inflammatory acne lesions and documenting changes in Physician Global Assessment scores. The majority of these findings are based on research exploring short-term outcomes, specifically over a six-month treatment period.

Evidence for Use in Premenstrual Dysphoric Disorder (PMDD)

Research examined the medication in randomized, double-blind trials that explored outcomes related to PMDD symptoms. Researchers used established scales to measure outcomes reflecting daily functioning and assessing patterns related to changes in the severity of emotional and physical symptoms. Findings were mixed due to similar patterns observed in the inactive control (placebo) groups in many of the trials. The evidence quality varies across studies, and primary trial follow-up durations were often limited to three to six months.

What Is Still Uncertain about the Research for Jade

The evidence base highlights several areas where certainty remains low or research is still needed. Follow-up durations were limited for the key outcomes related to acne and PMDD symptoms, meaning the long-term effects are not fully established. Additionally, comparative evidence is limited in some areas, particularly in high-quality trials that have examined the outcomes of this combination versus other combined hormonal contraceptives. Research highlights that outcomes related to subjective symptoms are often associated with changes observed in the placebo groups.

Key Studies & References

Effect and safety of drospirenone and ethinylestradiol tablets (II) for dysmenorrhea: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Jade (FAQ)

Q: What should I do if I miss a dose of Jade?

Official patient instructions indicate that a missed dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. The product information states that the dose should not be doubled to make up for a missed dose.

Q: Does Jade interact with other forms of contraception?

Official regulatory documents indicate that Jade may decrease the effectiveness of hormonal contraceptives, such as birth control pills, patches, rings, or injections. Regulatory information suggests the use of an additional, reliable non-hormonal method of birth control during treatment.

Q: What makes Drospirenone unique compared to other progestins?

Drospirenone, one of the two hormones in Jade, is described in official product information as having a unique characteristic. It is structurally related to spironolactone, which gives it an 'antimineralocorticoid activity.' This specific action helps differentiate it from some older progestins within the combined hormonal contraceptive class.

Q: How long do I have to take Jade before my iron levels decrease?

Clinical monitoring information indicates that changes in iron levels are assessed over time using specific lab tests, such as monthly serum ferritin measurements and Liver Iron Concentration (LIC) assessments every three to six months. Based on the trend of these indicators, dosage may be adjusted over a period of months to help achieve the desired reduction or maintenance of body iron burden.

Q: What should I do if I have an allergic reaction to Jade?

Official safety documents highlight that Jade carries a risk of hypersensitivity reactions, which can be severe. If signs of a severe allergic reaction occur, the drug's official label states that treatment should be stopped, and immediate medical care should be initiated.

How should Jade be stored and disposed of?

How to Store and Dispose of Jade (Drospirenone and Ethinyl Estradiol)

Jade must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication should be kept in the original container/blister packaging to protect the tablets from moisture and maintain stability.

Handling and Safety

It is a mandatory safety requirement that Jade be stored out of the sight and reach of children to prevent accidental ingestion. The tablets should not be stored outside of the permitted temperature excursion range.

Disposal

Unused or expired Jade must be disposed of properly via an official drug take-back program when available. Regulatory guidance instructs against discarding the tablets in household trash or flushing them down a toilet or sink to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Argentina

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z